1
|
Calligari P, Santucci V, Stella L, Bocchinfuso G. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state. Comput Struct Biotechnol J 2021; 19:6125-6139. [PMID: 34900129 PMCID: PMC8632847 DOI: 10.1016/j.csbj.2021.10.041] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 10/31/2021] [Accepted: 10/31/2021] [Indexed: 11/07/2022] Open
Abstract
The Src-homology 2 domain containing phosphatase 2 (SHP2) plays a critical role in crucial signaling pathways and is involved in oncogenesis and in developmental disorders. Its structure includes two SH2 domains (N-SH2 and C-SH2), and a protein tyrosine phosphatase (PTP) domain. Under basal conditions, SHP2 is auto-inhibited, with the N-SH2 domain blocking the PTP active site. Activation involves a rearrangement of the domains that makes the catalytic site accessible, coupled to the association between the SH2 domains and cognate proteins containing phosphotyrosines. Several aspects of this transition are debated and competing mechanistic models have been proposed. A crystallographic structure of SHP2 in an active state has been reported (PDB code 6crf), but several lines of evidence suggests that it is not fully representative of the conformations populated in solution. To clarify the structural rearrangements involved in SHP2 activation, enhanced sampling simulations of the autoinhibited and active states have been performed, for wild type SHP2 and its pathogenic E76K variant. Our results demonstrate that the crystallographic conformation of the active state is unstable in solution, and multiple interdomain arrangements are populated, thus allowing association to bisphosphorylated sequences. Contrary to a recent proposal, activation is coupled to the conformational changes of the N-SH2 binding site, which is significantly more accessible in the active sate, rather than to the structure of the central β-sheet of the domain. In this coupling, a previously undescribed role for the N-SH2 BG loop emerged.
Collapse
Key Words
- BTLA, B and T lymphocyte attenuator
- CTLA-4, cytotoxic T lymphocyte-associated antigen 4
- FRET, Förster resonance energy transfer
- Inter-domain dynamics
- JMML, juvenile myelomonocytic leukemia
- MD, molecular dynamics
- NS, Noonan syndrome
- NSML, Noonan syndrome with multiple lentigines
- PD-1, programmed cell death protein 1
- PDB, protein data bank
- PMF, potential of mean force
- PTP, protein tyrosine phosphatase
- Protein flexibility
- REMD, replica exchange molecular dynamics
- RMSD, root mean square deviation
- RMSF, root mean square fluctuation
- RTK, receptor tyrosine kinase
- Replica exchange molecular dynamics simulations
- SASA, solvent accessible surface area
- SAXS, small angle X-ray scattering
- SH2, Src homology 2
- SHP2 regulatory mechanism
- SHP2, Src homology 2 domain-containing phosphatase 2
- SIRPalpha, signal regulatory protein alpha
- pY, phosphorylated tyrosine
Collapse
Affiliation(s)
- Paolo Calligari
- Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma Tor Vergata, Rome, Italy
| | - Valerio Santucci
- Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma Tor Vergata, Rome, Italy
| | - Lorenzo Stella
- Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma Tor Vergata, Rome, Italy
| | - Gianfranco Bocchinfuso
- Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma Tor Vergata, Rome, Italy
| |
Collapse
|
2
|
Affiliation(s)
- Nader Rahal
- Department of Dermatology, Ha'emek Medical Center, Afula, Israel
| | - Amir Sadi
- Department of Dermatology, Ha'emek Medical Center, Afula, Israel
| | - Eran Cohen-Barak
- Department of Dermatology, Ha'emek Medical Center, Afula, Israel
| | - Michael Ziv
- Department of Dermatology, Ha'emek Medical Center, Afula, Israel
| | - Judit Krausz
- Department of Pathology, Ha'emek Medical Center, Afula, Israel
| | - Roni P Dodiuk-Gad
- Department of Dermatology, Ha'emek Medical Center, Afula, Israel.,Department of Medicine, University of Toronto, Toronto, Canada.,Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
| |
Collapse
|
3
|
Song Y, Zhao M, Wu Y, Yu B, Liu HM. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors. Acta Pharm Sin B 2021; 11:750-762. [PMID: 33777680 PMCID: PMC7982506 DOI: 10.1016/j.apsb.2020.10.021] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 08/01/2020] [Accepted: 08/21/2020] [Indexed: 12/11/2022] Open
Abstract
The protein tyrosine phosphatase Src homology phosphotyrosyl phosphatase 2 (SHP2) is implicated in various cancers, and targeting SHP2 has become a promising therapeutic approach. We herein described a robust cross-validation high-throughput screening protocol that combined the fluorescence-based enzyme assay and the conformation-dependent thermal shift assay for the discovery of SHP2 inhibitors. The established method can effectively exclude the false positive SHP2 inhibitors with fluorescence interference and was also successfully employed to identify new protein tyrosine phosphatase domain of SHP2 (SHP2-PTP) and allosteric inhibitors. Of note, this protocol showed potential for identifying SHP2 inhibitors against cancer-associated SHP2 mutation SHP2-E76A. After initial screening of our in-house compound library (∼2300 compounds), we identified 4 new SHP2-PTP inhibitors (0.17% hit rate) and 28 novel allosteric SHP2 inhibitors (1.22% hit rate), of which SYK-85 and WS-635 effectively inhibited SHP2-PTP (SYK-85: IC50 = 0.32 μmol/L; WS-635: IC50 = 4.13 μmol/L) and thus represent novel scaffolds for designing new SHP2-PTP inhibitors. TK-147, an allosteric inhibitor, inhibited SHP2 potently (IC50 = 0.25 μmol/L). In structure, TK-147 could be regarded as a bioisostere of the well characterized SHP2 inhibitor SHP-099, highlighting the essential structural elements for allosteric inhibition of SHP2. The principle underlying the cross-validation protocol is potentially feasible to identify allosteric inhibitors or those inactivating mutants of other proteins.
Collapse
Key Words
- AKT, protein kinase B
- ALK, anaplastic lymphoma kinase
- AML, acute myelogenous leukemia
- Allosteric inhibitors
- BTLA, B and T lymphocyte attenuator
- Bis-tris, bis-(2-hydroxyethyl)amino-tris(hydroxymethyl)methane
- DTT, dithiothreitol
- DiFMU, 6,8-difluoro-4-methylumbelliferyl hydroxid
- DiFMUP, 6,8-difluoro-4-methylumbelliferyl phosphate
- Enzyme assay
- FI, fluorescence intensity
- HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- HTS, high-throughput screening
- High-throughput screening
- IC50, half maximal inhibitory concentration
- JAK, janus kinase
- JMML, juvenile myelomonocytic leukaemia
- LB, lysogeny broth
- LOC, ligand only control
- LS, LEOPARD syndrome
- MAPK, mitogen-activated protein kinase
- MEK, extracellular regulated protein kinase kinases
- NPC, no protein control
- NS, Noonan syndrome
- OD, optical density
- PD-1, programmed death 1
- PI3K, phosphatidylinositol 3 kinase
- PMSF, phenylmethanesulfonyl fluoride
- PTP, protein tyrosine phosphatase
- R2, coefficient of determination
- RAS, rat sarcoma
- S/B, signal over background
- SD, standard deviation
- SDS-PAGE, sodium dodecyl sulphate polyacyrlamide gel electrophoresis
- SH2, Src homology 2
- SHP2
- SHP2, Src homology phosphotyrosyl phosphatase 2
- SHP2-PTP, protein tyrosine phosphatase domain of Src homology phosphotyrosyl phosphatase 2
- SHP2-WT, wild type Src homology phosphotyrosyl phosphatase 2
- STAT, signal transducer and activator of transcription
- Thermal shift assay
- Tm, melting temperature
- p-IRS1, phosphorylated insulin receptor substrate 1
- ΔTm, melting temperature change
Collapse
Affiliation(s)
- Yihui Song
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China
| | - Min Zhao
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China
| | - Yahong Wu
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Bin Yu
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China
| | - Hong-Min Liu
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China
| |
Collapse
|
4
|
Song Z, Wang M, Ge Y, Chen XP, Xu Z, Sun Y, Xiong XF. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. Acta Pharm Sin B 2021; 11:13-29. [PMID: 33532178 PMCID: PMC7838030 DOI: 10.1016/j.apsb.2020.07.010] [Citation(s) in RCA: 48] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 07/10/2020] [Accepted: 07/15/2020] [Indexed: 12/22/2022] Open
Abstract
Src homology containing protein tyrosine phosphatase 2 (SHP2) represents a noteworthy target for various diseases, serving as a well-known oncogenic phosphatase in cancers. As a result of the low cell permeability and poor bioavailability, the traditional inhibitors targeting the protein tyrosine phosphate catalytic sites are generally suffered from unsatisfactory applied efficacy. Recently, a particularly large number of allosteric inhibitors with striking inhibitory potency on SHP2 have been identified. In particular, few clinical trials conducted have made significant progress on solid tumors by using SHP2 allosteric inhibitors. This review summarizes the development and structure–activity relationship studies of the small-molecule SHP2 inhibitors for tumor therapies, with the purpose of assisting the future development of SHP2 inhibitors with improved selectivity, higher oral bioavailability and better physicochemical properties.
Collapse
Key Words
- ALK, anaplastic lymphoma kinase
- AML, acute myeloid leukemia
- Allosteric inhibitor
- B-ALL, B-cell acute lymphoblastic leukemia
- BTLA, B and T lymphocyte attenuator
- CADD, computer aided drug design
- CSF-1, colony stimulating factor-1
- CTLA-4, cytotoxic T lymphocyte-associated antigen-4
- EGFR, epidermal growth factor receptor
- ERK1/2, extracelluar signal-regulated kinase 1/2
- FLT3, Fms-like tyrosine kinase-3
- GAB2, Grb2-associated binding protein-2
- GRB2, growth factor receptor-bound protein 2
- HER2, human epidermal growth factor receptor-2
- HGF/SF, hepatocyte growth factor/scatter factor
- JAK, Janus kinase
- KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
- MAPK, mitogen-activated protein kinase
- NLRP3, NLR family, pyrin domain containing protein 3
- PD-1/PDL-1, programmed cell death protein-1/programmed death ligand-1
- PDAC, pancreatic ductal adenocarcinoma
- PDX, patient-derived xenograft
- PI3K, phosphatidylinositol 3 kinase
- PTK, protein tyrosine kinase
- PTP, protein tyrosine phosphatase
- Phosphatase
- RAS, rat sarcoma protein
- RTKs, receptor tyrosine kinase inhibitors
- SAR, structure–activity relationship
- SBDD, structure-based drug design
- SCC, squamous cell carcinoma
- SCNA, somatic copy number change
- SHP2
- SHP2, Src homology containing protein tyrosine phosphatase 2
- STAT, signal transducers and activators of transcription
- Selectivity
- TIGIT, T-cell immunoglobulin and ITIM domain protein
- TKIs, tyrosine kinase inhibitors
- Tumor therapy
- hERG, human ether-a-go-go-related gene
Collapse
Affiliation(s)
- Zhendong Song
- Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Meijing Wang
- State Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Sciences, Nanjing University, Nanjing 210023, China
| | - Yang Ge
- Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Xue-Ping Chen
- Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Ziyang Xu
- State Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Sciences, Nanjing University, Nanjing 210023, China
| | - Yang Sun
- State Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Sciences, Nanjing University, Nanjing 210023, China
| | - Xiao-Feng Xiong
- Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| |
Collapse
|
5
|
Ścibior A, Pietrzyk Ł, Plewa Z, Skiba A. Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends. J Trace Elem Med Biol 2020; 61:126508. [PMID: 32305626 PMCID: PMC7152879 DOI: 10.1016/j.jtemb.2020.126508] [Citation(s) in RCA: 80] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 02/25/2020] [Accepted: 03/19/2020] [Indexed: 01/21/2023]
Abstract
BACKGROUND Vanadium (V) is an element with a wide range of effects on the mammalian organism. The ability of this metal to form organometallic compounds has contributed to the increase in the number of studies on the multidirectional biological activity of its various organic complexes in view of their application in medicine. OBJECTIVE This review aims at summarizing the current state of knowledge of the pharmacological potential of V and the mechanisms underlying its anti-viral, anti-bacterial, anti-parasitic, anti-fungal, anti-cancer, anti-diabetic, anti-hypercholesterolemic, cardioprotective, and neuroprotective activity as well as the mechanisms of appetite regulation related to the possibility of using this element in the treatment of obesity. The toxicological potential of V and the mechanisms of its toxic action, which have not been sufficiently recognized yet, as well as key information about the essentiality of this metal, its physiological role, and metabolism with certain aspects on the timeline is collected as well. The report also aims to review the use of V in the implantology and industrial sectors emphasizing the human health hazard as well as collect data on the directions of further research on V and its interactions with Mg along with their character. RESULTS AND CONCLUSIONS Multidirectional studies on V have shown that further analyses are still required for this element to be used as a metallodrug in the fight against certain life-threatening diseases. Studies on interactions of V with Mg, which showed that both elements are able to modulate the response in an interactive manner are needed as well, as the results of such investigations may help not only in recognizing new markers of V toxicity and clarify the underlying interactive mechanism between them, thus improving the medical application of the metals against modern-age diseases, but also they may help in development of principles of effective protection of humans against environmental/occupational V exposure.
Collapse
Key Words
- 3-HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA
- AIDS, acquired immune deficiency syndrome
- ALB, albumin
- ALP, alkaline phosphatase
- AS, antioxidant status
- Akt, protein kinase B (PKB)
- AmD, Assoc American Dietetic Association
- Anti-B, anti-bacterial
- Anti-C, anti-cancer
- Anti-D, anti-diabetic
- Anti-F, anti-fungal
- Anti-O, anti-obesity
- Anti-P, anti-parasitic
- Anti-V, anti-viral
- Anti−HC, anti-hypercholesterolemic
- ApoA-I, apolipoprotein A
- ApoB, apolipoprotein B
- B, bone
- BCOV, bis(curcumino)oxavanadyl
- BEOV, bis(ethylmaltolato)oxovanadium
- BMOV, bis(maltolato)oxavanadium(IV)
- Bim, Blc-2 interacting mediator of cell death
- Biological role
- BrOP, bromoperoxidase
- C, cholesterol
- C/EBPα, CCAAT-enhancer-binding protein α
- CD4, CD4 receptor
- CH, cerebral hemisphere
- CHO-K1, Chinese hamster ovary cells
- CXCR-4, CXCR-4 chemokine co-receptor
- Cardio-P, cardioprotective
- Citrate-T, citrate transporter
- CoA, coenzyme A
- Cyt c, cytochrome c
- DM, diabetes mellitus
- ELI, extra low interstitial
- ERK, extracellular regulated kinase
- FHR, fructose hypertensive rats
- FKHR/FKHR1/AFX, class O members of the forkhead transcription factor family
- FLIP, FLICE-inhibitory protein
- FOXOs, forkhead box class O family member proteins
- FPP, farnesyl-pyrophosphate
- FasL, Fas ligand, FER: ferritin
- GI, gastrointestinal
- GLU, glucose
- GLUT-4, glucose transporter type 4
- GPP, geranyl-pyrophosphate
- GPT, glutamate-pyruvate transaminase
- GR, glutathione reductase
- GSH, reduced glutathione
- GSSG, disulfide glutathione
- HDL, high-density lipoproteins
- HDL-C, HDL cholesterol
- HIV, human immunodeficiency virus
- HMMF, high molecular mass fraction
- HOMA-IR, insulin resistance index
- Hb, hemoglobin
- HbF, hemoglobin fraction
- Hyper-LEP, hyperleptynemia
- IDDM, insulin-dependent diabetes mellitus
- IGF-IR, insulin-like growth factor receptor
- IL, interleukin
- INS, insulin
- INS-R, insulin resistance
- INS-S, insulin sensitivity
- IPP, isopentenyl-5-pyrophosphate
- IRS, insulin receptor tyrosine kinase substrate
- IgG, immunoglobulin G
- Industrial importance
- Interactions
- JAK2, Janus kinase 2
- K, kidney
- L, liver
- L-AA, L-ascorbic acid
- LDL, low-density lipoproteins
- LDL-C, LDL cholesterol
- LEP, leptin
- LEP-R, leptin resistance
- LEP-S, leptin sensitivity
- LEPS, the concentration of leptin in the serum
- LMMF, low molecular mass fraction
- LPL, lipoprotein lipase
- LPO, lipid peroxidation
- Lactate-T, lactate transporter
- M, mitochondrion
- MEK, ERK kinase activator
- MRC, mitochondrial respiratory chain
- NAC, N-acetylcysteine
- NEP, neutral endopeptidase
- NIDDM, noninsulin-dependent diabetes mellitus
- NO, nitric oxide
- NPY, neuropeptide Y
- NaVO3, sodium metavanadate
- Neuro-P, neuroprotective
- OXPHOS, oxidative phosphorylation
- Organic-AT, organic anion transporter
- Over-W, over-weight
- P, plasma
- PANC-1, pancreatic ductal adenocarcinoma cells
- PARP, poly (ADP-ribose) polymerase
- PLGA, (Poly)Lactide-co-Glycolide copolymer
- PO43−, phosphate ion
- PPARγ, peroxisome-activated receptor γ
- PTK, tyrosine protein kinase
- PTP, protein tyrosine phosphatase
- PTP-1B, protein tyrosine phosphatase 1B
- Pharmacological activity
- Pi3K, phosphoinositide 3-kinase (phosphatidylinositol 3-kinase)
- RBC, erythrocytes
- ROS, reactive oxygen species
- RT, reverse transcriptase
- SARS, severe acute respiratory syndrome
- SAcP, acid phosphatase secreted by Leshmania
- SC-Ti-6Al-4V, surface-coated Ti-6Al-4V
- SHR, spontaneously hypertensive rats
- SOD, superoxide dismutase
- STAT3, signal transducer/activator of transcription 3
- Sa, mean roughness
- Sq, root mean square roughness
- Sz, ten-point height
- TC, total cholesterol
- TG, triglycerides
- TS, transferrin saturation
- Tf, transferrin
- TfF, transferrin fraction
- TiO2, nHA:Ag-Ti-6Al-4V: titanium oxide-based coating containing hydroxyapatite nanoparticle and silver particles
- Top-IB, IB type topoisomerase
- Toxicological potential
- V, vanadium
- V-BrPO, vanadium bromoperoxidase
- V-DLC, diamond-like layer with vanadium
- V5+/V4+, pentavalent/tetravalent vanadium
- VO2+, vanadyl cation
- VO2+-FER, vanadyl-ferritin complex
- VO4-/VO3-, vanadate anion
- VO43-, vanadate ion
- VS, vanadyl sulfate
- Vanadium
- WB, whole blood
- ZDF rats, Zucker diabetic fatty rats
- ZF rats, Zucker fatty rats
- breakD, breakdown
- eNOS, endothelial nitric oxide synthase
- mo, months
- n-HA, nano-hydroxyapatite
- pRb, retinoblastoma protein
- wk, weeks
Collapse
Affiliation(s)
- Agnieszka Ścibior
- Laboratory of Oxidative Stress, Centre for Interdisciplinary Research, The John Paull II Catholic University of Lublin, Poland
| | - Łukasz Pietrzyk
- Laboratory of Oxidative Stress, Centre for Interdisciplinary Research, The John Paull II Catholic University of Lublin, Poland
- Department of Didactics and Medical Simulation, Chair of Anatomy, Medical University of Lublin, Poland
| | - Zbigniew Plewa
- Department of General, Oncological, and Minimally Invasive Surgery, 1 Military Clinical Hospital with the Outpatient Clinic in Lublin, Poland
| | - Andrzej Skiba
- Military Clinical Hospital with the Outpatient Clinic in Lublin, Poland
| |
Collapse
|
6
|
Abdel-Rahman RF, Ezzat SM, Ogaly HA, Abd-Elsalam RM, Hessin AF, Fekry MI, Mansour DF, Mohamed SO. Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: a new insight into its antidiabetic mechanism. J Nutr Sci 2020; 9:e2. [PMID: 32042410 PMCID: PMC6984126 DOI: 10.1017/jns.2019.40] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Revised: 11/29/2019] [Accepted: 12/03/2019] [Indexed: 12/14/2022] Open
Abstract
Ficus deltoidea var. deltoidea Jack (FD) is a well-known plant used in Malay folklore medicine to lower blood glucose in diabetic patients. For further research of the antihyperglycemic mechanisms, the protein tyrosine phosphatase 1B (PTP1B)-inhibitory effect of FD was analysed both in vitro and in vivo. To optimise a method for FD extraction, water, 50, 70, 80, 90 and 95 % ethanol extracts were prepared and determined for their total phenolic and triterpene contents, and PTP1B-inhibition capacity. Among the tested extracts, 70 % ethanol FD extract showed a significant PTP1B inhibition (92·0 % inhibition at 200 µg/ml) and high phenolic and triterpene contents. A bioassay-guided fractionation of the 70 % ethanol extract led to the isolation of a new triterpene (3β,11β-dihydroxyolean-12-en-23-oic acid; F3) along with six known compounds. In vivo, 4 weeks' administration of 70 % ethanol FD extract (125, 250 and 500 mg/kg/d) to streptozotocin-nicotinamide-induced type 2 diabetic rats reversed the abnormal changes of blood glucose, insulin, total Hb, GLUT2, lipid profile, and oxidative stress in liver and pancreas. Moreover, FD reduced the mRNA expression of the key gluconeogenic enzymes (phosphoenolpyruvate carboxykinase and glucose 6-phosphatase) and restored insulin receptor and GLUT2 encoding gene (Slc2a2) expression. In addition, FD significantly down-regulated the hepatic PTP1B gene expression. These results revealed that FD could potentially improve insulin sensitivity, suppress hepatic glucose output and enhance glucose uptake in type 2 diabetes mellitus through down-regulation of PTP1B. Together, our findings give scientific evidence for the traditional use of FD as an antidiabetic agent.
Collapse
Key Words
- CAT, catalase
- Dihydroxyolean-12-en-23-oic acid
- FBG, fasting blood glucose
- FD, Ficus deltoidea var. deltoidea Jack
- Ficus deltoidea
- G6Pase, glucose 6-phosphatase
- GPx, glutathione peroxidase
- GSH, reduced glutathione
- Glucose 6-phosphatase
- Glucose transporter-2
- MDA, malondialdehyde
- MET, metformin
- NA, nicotinamide
- PEPCK, phosphoenolpyruvate carboxykinase
- PTP, protein tyrosine phosphatase
- Phosphoenolpyruvate carboxykinase
- Protein tyrosine phosphatase 1B
- SOD, superoxide dismutase
- STZ, streptozotocin
- Slc2a2, GLUT2 gene
- T2DM, type 2 diabetes mellitus
Collapse
Affiliation(s)
| | - Shahira M. Ezzat
- Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr El-Einy Street, Cairo11562, Egypt
- Pharmacognosy Department, Faculty of Pharmacy, October University for Modern Sciences and Arts, 6th October Campus, 12566, Egypt
| | - Hanan A. Ogaly
- Chemistry Department, College of Science, King Khalid University, Abha, Saudi Arabia
- Biochemistry Department, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
| | - Reham M. Abd-Elsalam
- Pathology Department, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
| | - Alyaa F. Hessin
- Pharmacology Department, National Research Centre, Giza, Egypt
- Microbiology and Immunology Department, College of Medicine, University of Illinois, Chicago, IL, USA
| | - Mostafa I. Fekry
- Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr El-Einy Street, Cairo11562, Egypt
| | - Dina F. Mansour
- Pharmacology Department, National Research Centre, Giza, Egypt
| | - Shanaz O. Mohamed
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia
| |
Collapse
|
7
|
Coulombe G, Rivard N. New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract. Cell Mol Gastroenterol Hepatol 2015; 2:11-21. [PMID: 28174704 PMCID: PMC4980741 DOI: 10.1016/j.jcmgh.2015.11.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Accepted: 11/10/2015] [Indexed: 12/13/2022]
Abstract
SHP-2 is a tyrosine phosphatase expressed in most embryonic and adult tissues. SHP-2 regulates many cellular functions including growth, differentiation, migration, and survival. Genetic and biochemical evidence show that SHP-2 is required for rat sarcoma viral oncogene/extracellular signal-regulated kinases mitogen-activated protein kinase pathway activation by most tyrosine kinase receptors, as well as by G-protein-coupled and cytokine receptors. In addition, SHP-2 can regulate the Janus kinase/signal transducers and activators of transcription, nuclear factor-κB, phosphatidyl-inositol 3-kinase/Akt, RhoA, Hippo, and Wnt/β-catenin signaling pathways. Emerging evidence has shown that SHP-2 dysfunction represents a key factor in the pathogenesis of gastrointestinal diseases, in particular in chronic inflammation and cancer. Variations within the gene locus encoding SHP-2 have been associated with increased susceptibility to develop ulcerative colitis and gastric atrophy. Furthermore, mice with conditional deletion of SHP-2 in intestinal epithelial cells rapidly develop severe colitis. Similarly, hepatocyte-specific deletion of SHP-2 induces hepatic inflammation, resulting in regenerative hyperplasia and development of tumors in aged mice. However, the SHP-2 gene initially was suggested to be a proto-oncogene because activating mutations of this gene were found in pediatric leukemias and certain forms of liver and colon cancers. Moreover, SHP-2 expression is up-regulated in gastric and hepatocellular cancers. Notably, SHP-2 functions downstream of cytotoxin-associated antigen A (CagA), the major virulence factor of Helicobacter pylori, and is associated with increased risks of gastric cancer. Further compounding this complexity, most recent findings suggest that SHP-2 also coordinates carbohydrate, lipid, and bile acid synthesis in the liver and pancreas. This review aims to summarize current knowledge and recent data regarding the biological functions of SHP-2 in the gastrointestinal tract.
Collapse
Key Words
- CagA, cytotoxin-associated gene A
- ERK, extracellular signal-regulated kinases
- FGF, fibroblast growth factor
- GI, gastrointestinal
- HCC, hepatocellular carcinoma
- IBD, inflammatory bowel disease
- IEC, intestinal epithelial cell
- JMML, juvenile myelomonocytic leukemia
- KO, knockout
- MAPK, mitogen-activated protein kinase
- NF-κB, nuclear factor-κB
- PI3K, phosphatidyl-inositol 3-kinase
- PTP, protein tyrosine phosphatase
- PTPN11
- RAS, rat sarcoma viral oncogene
- epithelium
- gastrointestinal cancer
- inflammation
Collapse
Affiliation(s)
| | - Nathalie Rivard
- Correspondence Address correspondence to: Nathalie Rivard, PhD, 3201, Jean Mignault, Sherbrooke, Quebec, Canada, J1E4K8.3201Jean Mignault, SherbrookeQuebecCanada, J1E4K8
| |
Collapse
|
8
|
Abstract
Epithelial cells are tightly coupled together through specialized intercellular junctions, including adherens junctions, desmosomes, tight junctions, and gap junctions. A growing body of evidence suggests epithelial cells also directly exchange information at cell-cell contacts via the Eph family of receptor tyrosine kinases and their membrane-associated ephrin ligands. Ligand-dependent and -independent signaling via Eph receptors as well as reverse signaling through ephrins impact epithelial tissue homeostasis by organizing stem cell compartments and regulating cell proliferation, migration, adhesion, differentiation, and survival. This review focuses on breast, gut, and skin epithelia as representative examples for how Eph receptors and ephrins modulate diverse epithelial cell responses in a context-dependent manner. Abnormal Eph receptor and ephrin signaling is implicated in a variety of epithelial diseases raising the intriguing possibility that this cell-cell communication pathway can be therapeutically harnessed to normalize epithelial function in pathological settings like cancer or chronic inflammation.
Collapse
Key Words
- ADAM, a disintegrin and metalloprotease
- Apc, adenomatous polyposis coli
- Breast
- ER, estrogen receptor
- Eph receptor
- Eph, erythropoietin-producing hepatocellular
- Erk, extracellular signal-regulated kinase
- GEF, guanine nucleotide exchange factor
- GPI, glycosylphosphatidylinositol
- HER2, human epidermal growth factor receptor 2
- HGF, hepatocyte growth factor
- IBD, inflammatory bowel disease
- KLF, Krüppel-like factor
- MAPK, mitogen-activated protein kinase
- MMTV-LTR, mouse mammary tumor virus-long terminal repeat
- MT1-MMP, membrane-type 1 matrix metalloproteinase
- PDZ, postsynaptic density protein 95, discs large 1, and zonula occludens-1
- PTP, protein tyrosine phosphatase
- RTK, receptor tyrosine kinase
- SH2, Src homology 2
- SHIP2, SH2 inositol phosphatase 2
- SLAP, Src-like adaptor protein
- TCF, T-cell specific transcription factor
- TEB, terminal end bud
- TNFα, tumor necrosis factor α.
- cell-cell
- ephrin
- epithelial
- intestine
- receptor tyrosine kinase
- skin
- stem cell
Collapse
|
9
|
Krüger J, Brachs S, Trappiel M, Kintscher U, Meyborg H, Wellnhofer E, Thöne-Reineke C, Stawowy P, Östman A, Birkenfeld AL, Böhmer FD, Kappert K. Enhanced insulin signaling in density-enhanced phosphatase-1 (DEP-1) knockout mice. Mol Metab 2015; 4:325-36. [PMID: 25830095 PMCID: PMC4354926 DOI: 10.1016/j.molmet.2015.02.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Revised: 01/30/2015] [Accepted: 02/04/2015] [Indexed: 01/06/2023] Open
Abstract
Objective Insulin resistance can be triggered by enhanced dephosphorylation of the insulin receptor or downstream components in the insulin signaling cascade through protein tyrosine phosphatases (PTPs). Downregulating density-enhanced phosphatase-1 (DEP-1) resulted in an improved metabolic status in previous analyses. This phenotype was primarily caused by hepatic DEP-1 reduction. Methods Here we further elucidated the role of DEP-1 in glucose homeostasis by employing a conventional knockout model to explore the specific contribution of DEP-1 in metabolic tissues. Ptprj−/− (DEP-1 deficient) and wild-type C57BL/6 mice were fed a low-fat or high-fat diet. Metabolic phenotyping was combined with analyses of phosphorylation patterns of insulin signaling components. Additionally, experiments with skeletal muscle cells and muscle tissue were performed to assess the role of DEP-1 for glucose uptake. Results High-fat diet fed-Ptprj−/− mice displayed enhanced insulin sensitivity and improved glucose tolerance. Furthermore, leptin levels and blood pressure were reduced in Ptprj−/− mice. DEP-1 deficiency resulted in increased phosphorylation of components of the insulin signaling cascade in liver, skeletal muscle and adipose tissue after insulin challenge. The beneficial effect on glucose homeostasis in vivo was corroborated by increased glucose uptake in skeletal muscle cells in which DEP-1 was downregulated, and in skeletal muscle of Ptprj−/− mice. Conclusion Together, these data establish DEP-1 as novel negative regulator of insulin signaling.
Collapse
Key Words
- DEP-1, density-enhanced phosphatase-1
- Density-enhanced phosphatase-1
- GTT, glucose tolerance test
- Glucose homeostasis
- HFD, high-fat diet
- IL-6, interleukin 6
- IR, insulin receptor
- ITT, insulin tolerance test
- Insulin resistance
- Insulin signaling
- KO, knockout
- LFD, low-fat diet
- MCP-1, monocyte chemotactic protein-1
- PTP, protein tyrosine phosphatase
- Phosphorylation
- RER, respiratory exchange ratio
- RTK, receptor tyrosine kinase
- WT, wild-type
Collapse
Affiliation(s)
- Janine Krüger
- Center for Cardiovascular Research/CCR, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Hessische Str. 3-4, 10115 Berlin, Charité - Universitätsmedizin Berlin, Germany
| | - Sebastian Brachs
- Center for Cardiovascular Research/CCR, Department of Endocrinology, Diabetes and Nutrition, Hessische Str. 3-4, 10115 Berlin, Charité - Universitätsmedizin Berlin, Germany
| | - Manuela Trappiel
- Center for Cardiovascular Research/CCR, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Hessische Str. 3-4, 10115 Berlin, Charité - Universitätsmedizin Berlin, Germany
| | - Ulrich Kintscher
- Center for Cardiovascular Research/CCR, Institute of Pharmacology, Hessische Str. 3-4, 10115 Berlin, Charité - Universitätsmedizin Berlin, Germany
| | - Heike Meyborg
- Department of Medicine/Cardiology, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Ernst Wellnhofer
- Department of Medicine/Cardiology, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Christa Thöne-Reineke
- Center for Cardiovascular Research/CCR, Department of Experimental Medicine, Hessische Str. 3-4, 10115 Berlin, Charité - Universitätsmedizin Berlin, Germany
| | - Philipp Stawowy
- Department of Medicine/Cardiology, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Arne Östman
- Cancer Center Karolinska, R8:03, Department of Oncology-Pathology, Karolinska Institutet, 171 76 Stockholm, Sweden
| | - Andreas L Birkenfeld
- Center for Cardiovascular Research/CCR, Department of Endocrinology, Diabetes and Nutrition, Hessische Str. 3-4, 10115 Berlin, Charité - Universitätsmedizin Berlin, Germany
| | - Frank D Böhmer
- Center for Molecular Biomedicine, Institute of Molecular Cell Biology, Universitätsklinikum Jena, Hans-Knöll-Str. 2, 07745 Jena, Germany
| | - Kai Kappert
- Center for Cardiovascular Research/CCR, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Hessische Str. 3-4, 10115 Berlin, Charité - Universitätsmedizin Berlin, Germany
| |
Collapse
|
10
|
Hempel N, Melendez JA. Intracellular redox status controls membrane localization of pro- and anti-migratory signaling molecules. Redox Biol 2014; 2:245-50. [PMID: 24494199 PMCID: PMC3909818 DOI: 10.1016/j.redox.2014.01.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Accepted: 01/09/2014] [Indexed: 01/07/2023] Open
Abstract
Shifts in intracellular Reactive Oxygen Species (ROS) have been shown to contribute to carcinogenesis and to tumor progression. In addition to DNA and cell damage by surges in ROS, sub-lethal increases in ROS are implicated in regulating cellular signaling that enhances pro-metastatic behavior. We previously showed that subtle increases in endogenous H2O2 regulate migratory and invasive behavior of metastatic bladder cancer cells through phosphatase inhibition and consequential phosphorylation of p130cas, an adapter of the FAK signaling pathway. We further showed that enhanced redox status contributed to enhanced localization of p130cas to the membrane of metastatic cells. Here we show that this signaling complex can similarly be induced in a redox-engineered cell culture model that enables regulation of intracellular steady state H2O2 level by enforced expression of superoxide dismutase 2 (Sod2) and catalase. Expression of Sod2 leads to enhanced p130cas phosphorylation in HT-1080 fibrosarcoma and UM-UC-6 bladder cancer cells. These changes are mediated by H2O2, as co-expression of Catalase abrogates p130cas phosphorylation and its interaction with the adapter protein Crk. Importantly, we establish that the redox environment influence the localization of the tumor suppressor and phosphatase PTEN, in both redox-engineered and metastatic bladder cancer cells that display endogenous increases in H2O2. Importantly, PTEN oxidation leads to its dissociation from the plasma membrane. This indicates that oxidation of PTEN not only influences its activity, but also regulates its cellular localization, effectively removing it from its primary site of lipid phosphatase activity. These data introduce hitherto unappreciated paradigms whereby ROS can reciprocally regulate the cellular localization of pro- and anti-migratory signaling molecules, p130cas and PTEN, respectively. These data further confirm that altering antioxidant status and the intracellular ROS environment can have profound effects on pro-metastatic signaling pathways. Sod2-mediated increases in steady state H2O2 enhance phosphorylation of the focal adhesion adapter protein p130cas, which regulates migration. Sod2-dependent changes in steady state H2O2 increase membrane recruitment of p130cas. H2O2 controls the oxidation-dependent recruitment of PTEN from the plasma membrane to the cytosol. Intracellular shifts in ROS can reciprocally regulate the cellular localization of pro- and anti-migratory signaling molecules, p130cas and PTEN respectively.
Collapse
Key Words
- CAT, catalase
- FAK, focal adhesion kinase
- H2O2, hydrogen peroxide
- MMP, matrix metalloproteinase
- Nox, NADPH oxidase
- PIP3, phosphatidylinositol (3,4,5)-trisphosphate
- PTEN
- PTEN, phosphatase and tensin homolog
- PTP, protein tyrosine phosphatase
- ROS, reactive oxygen species
- Redox signaling
- Sod2
- Sod2, manganese superoxide dismutase
- p130cas
- p130cas, Crk-associated substrate
Collapse
Affiliation(s)
- Nadine Hempel
- Nanobioscience Constellation, SUNY College of Nanoscale Sciences and Engineering, 257 Fuller Rd., NFE-4313, Albany, NY 12203, USA
| | - J Andres Melendez
- Nanobioscience Constellation, SUNY College of Nanoscale Sciences and Engineering, 257 Fuller Rd., NFE-4313, Albany, NY 12203, USA
| |
Collapse
|
11
|
Abstract
Considerable efforts have been invested to understand the mechanisms by which pro-inflammatory cytokines mediate the demise of β-cells in type 1 diabetes but much less attention has been paid to the role of anti-inflammatory cytokines as potential cytoprotective agents in these cells. Despite this, there is increasing evidence that anti-inflammatory molecules such as interleukin (IL)-4, IL-10 and IL-13 can exert a direct influence of β-cell function and viability and that the circulating levels of these cytokines may be reduced in type 1 diabetes. Thus, it seems possible that targeting of anti-inflammatory pathways might offer therapeutic potential in this disease. In the present review, we consider the evidence implicating IL-4, IL-10 and IL-13 as cytoprotective agents in the β-cell and discuss the receptor components and downstream signaling pathways that mediate these effects.
Collapse
Affiliation(s)
- M A Russell
- Institute of Biomedical and Clinical Science; University of
Exeter Medical School; Exeter, Devon, UK
- Correspondence to: MA
Russell;
| | - N G Morgan
- Institute of Biomedical and Clinical Science; University of
Exeter Medical School; Exeter, Devon, UK
| |
Collapse
|